Latest news with #Y-mAbsTherapeutics
Yahoo
28-05-2025
- Business
- Yahoo
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C. The presentation marks a significant update in its experimental pipeline. The trial-in-progress poster contained findings from Trial 1001, a Phase 1 study assessing GD2-SADA Pretargeted Radioimmunotherapy using 177Lu-DOTA in patients with high-risk neuroblastoma and other GD2-expressing tumors. A scientist in a lab coat, holding a beaker of a biopharmaceutical creation. The focus of the company's presentation was on radioimmunotherapy innovation. The GD2-SADA construct, developed in a partnership with Memorial Sloan Kettering Cancer Center, deploys a two-step process allowing localized irradiation of tumors while limiting off-target toxicity. Trial 1001 has now completed Part A and has identified the optimal dosage for the GD2-SADA protein. It is currently being prepared for further evaluation. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has scheduled to deliver its initial data readout during its virtual R&D update on May 28. The company's stock gained 5.37% in the past week right before the new unveiling, reflecting investor confidence in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)'s proprietary Self-Assembly DisAssembly (SADA) platform as well as the upcoming clinical milestones. Analysts remain bullish, offering a consensus Buy rating, while projecting an average price target of $16.50 with an upside potential of 281.94%. While we acknowledge the potential of YMAB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than YMAB and that has 100x upside potential, check out our report about the READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds Disclosure: None. Sign in to access your portfolio
Yahoo
27-05-2025
- Business
- Yahoo
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C. The presentation marks a significant update in its experimental pipeline. The trial-in-progress poster contained findings from Trial 1001, a Phase 1 study assessing GD2-SADA Pretargeted Radioimmunotherapy using 177Lu-DOTA in patients with high-risk neuroblastoma and other GD2-expressing tumors. A scientist in a lab coat, holding a beaker of a biopharmaceutical creation. The focus of the company's presentation was on radioimmunotherapy innovation. The GD2-SADA construct, developed in a partnership with Memorial Sloan Kettering Cancer Center, deploys a two-step process allowing localized irradiation of tumors while limiting off-target toxicity. Trial 1001 has now completed Part A and has identified the optimal dosage for the GD2-SADA protein. It is currently being prepared for further evaluation. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has scheduled to deliver its initial data readout during its virtual R&D update on May 28. The company's stock gained 5.37% in the past week right before the new unveiling, reflecting investor confidence in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)'s proprietary Self-Assembly DisAssembly (SADA) platform as well as the upcoming clinical milestones. Analysts remain bullish, offering a consensus Buy rating, while projecting an average price target of $16.50 with an upside potential of 281.94%. While we acknowledge the potential of YMAB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than YMAB and that has 100x upside potential, check out our report about the READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
26-05-2025
- Business
- Yahoo
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the 'Company' or 'Y-mAbs') (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of GD2-SADA in recurrent or refractory metastatic solid tumors known to express GD2 in a trial in progress poster at the Advances in Neuroblastoma Research Meeting ('ANR') being held on May 25-28, 2025 in Washington, D.C. The trial in progress poster titled 'A phase 1 trial of pretargeted radioimmunotherapy with GD2-SADA: 177Lu-DOTA in patients with high-risk neuroblastoma and other GD2+ solid tumors' provides an overview of Trial 1001 (NCT05130255), a first-in-human, dose-escalation, single-arm, open-label, nonrandomized, multicenter Phase 1 clinical trial evaluating the safety and tolerability of GD2-SADA Pretargeted Radioimmunotherapy ('GD2-SADA PRIT') with Lutetium 177 DOTA (177Lu-DOTA) in adult and adolescent patients (≥ 16 years of age and older) with recurrent or refractory metastatic GD2-expressing solid tumors, including high-risk neuroblastoma ('HR NB'), small cell lung cancer, sarcoma, and melanoma. Part A of the trial includes dose escalation of GD2-SADA protein to define the optimal safe dose of this self-assembling and disassembling protein and will also evaluate the administration interval between GD2-SADA and 177Lu-DOTA. 'We are pleased to present data from our ongoing Trial 1001 in patients with high-risk neuroblastoma and other GD2-positive tumors,' said Norman LaFrance, M.D., Chief Medical and Development Officer. 'We have completed Part A and we look forward to providing the initial data readout during our virtual Radiopharmaceutical R&D update on May 28th.' The abstract details are below: Abstract Title: 'A phase 1 trial of pretargeted radioimmunotherapy with GD2-SADA: 177Lu-DOTA in patients with high-risk neuroblastoma and other GD2+ solid tumors'Format: Poster Presentation, Poster Session Group B, Poster # 246Date and Time: Monday, May 26, 2025 at 4:40 p.m. – 5:10 p.m. ET About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company's technologies include its investigational Self-Assembly DisAssembly ('SADA') Pretargeted Radioimmunotherapy Platform ('PRIT') and bispecific antibodies. The Company's broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. About GD2-SADA PRITGD2-SADA is a bispecific fusion protein that tightly binds to the tumor-associated antigen GD2 and Lutetium 177 DOTA (177Lu-DOTA), a chelated or 'caged' radionuclide. In the first step of pre-targeted radiotherapy, non-radiolabeled GD2-SADA tetramers are infused and bind to GD2-positive solid tumors, and unbound GD2-SADA protein disassembles into low molecular weight monomers that are removed by the kidney. The second infusion delivers the 'radioactive payload,' which binds directly to GD2-SADA on tumor cells for localized irradiation. GD2-SADA PRIT with 177Lutetium-DOTA has demonstrated robust anti-tumor efficacy in preclinical studies and is currently being investigated in adults and adolescents with GD2-expressing solid tumors in Trial 1001 (NCT05130255). Researchers at Memorial Sloan Kettering Cancer Center (MSK), including Dr. Nai-Kong Cheung, developed the SADA technology for radioimmunotherapy, which is exclusively licensed by MSK to Y-mAbs. Dr. Cheung has intellectual property rights and interests in the technology, and as a result of this licensing arrangement, MSK has institutional financial interests in the technology. Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2025 and beyond. Words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'hope,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would,' 'guidance,' 'goal,' 'objective,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company's business is subject to risks and uncertainties affecting the Company including those described in the 'Risk Factors' section included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and the Company's Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2025, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. SADA®, SADA PRIT™, DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc. CONTACT: Investor Contact: Courtney Dugan VP, Head of Investor Relations cdu@ in to access your portfolio
Business Insider
28-04-2025
- Health
- Business Insider
Y-mAbs Therapeutics announces presentation of PK data of CD38-SADA
Y-mAbs Therapeutics (YMAB) announced the presentation of preclinical and translational pharmacokinetics, PK, data of CD38-SADA in a poster at the 2025 American Association of Cancer Research, AACR, Annual Meeting being held on April 25-30, 2025 in Chicago, IL. The poster titled 'Preclinical and translational pharmacokinetic modeling of the self-assembling and disassembling, SADA, bispecific fusion protein CD38-SADA for first-in-human pretargeted radioimmunotherapy' characterizes the plasma concentrations of CD38-SADA in animal models over time and a range of doses. Utilizing in vitro binding kinetic parameters and PK data generated from three studies in mice, the study characterized the concentration- and time-dependent equilibrium between CD38-SADA tetramers and monomers Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Yahoo
09-03-2025
- Business
- Yahoo
Bearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimates
The analysts covering Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Both revenue and earnings per share (EPS) estimates were cut sharply as analysts factored in the latest outlook for the business, concluding that they were too optimistic previously. Following the latest downgrade, Y-mAbs Therapeutics' ten analysts currently expect revenues in 2025 to be US$87m, approximately in line with the last 12 months. Per-share losses are expected to explode, reaching US$0.96 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$106m and losses of US$0.66 per share in 2025. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase. See our latest analysis for Y-mAbs Therapeutics The consensus price target fell 12% to US$18.00, implicitly signalling that lower earnings per share are a leading indicator for Y-mAbs Therapeutics' valuation. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Y-mAbs Therapeutics' past performance and to peers in the same industry. We would highlight that sales are expected to reverse, with a forecast 0.8% annualised revenue decline to the end of 2025. That is a notable change from historical growth of 42% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 20% per year. It's pretty clear that Y-mAbs Therapeutics' revenues are expected to perform substantially worse than the wider industry. The most important thing to take away is that analysts increased their loss per share estimates for this year. Unfortunately analysts also downgraded their revenue estimates, and industry data suggests that Y-mAbs Therapeutics' revenues are expected to grow slower than the wider market. After such a stark change in sentiment from analysts, we'd understand if readers now felt a bit wary of Y-mAbs Therapeutics. Still, the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Y-mAbs Therapeutics analysts - going out to 2027, and you can see them free on our platform here. Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
